Rebecca Lim1, Ruth Muljadi2, Eugenia Koulaeva3, Patricia Vosdoganes3, Siow Teng Chan2, Rutu Acharya2, Seshini Gurusinghe2, Olli Ritvos4, Arja Pasternack4, Euan M Wallace1. 1. 1] The Ritchie Centre, MIMR-PHI Institute of Medical Research, Victoria, Australia [2] Department of Obstetrics and Gynecology, Monash University, Victoria, Australia. 2. The Ritchie Centre, MIMR-PHI Institute of Medical Research, Victoria, Australia. 3. Department of Obstetrics and Gynecology, Monash University, Victoria, Australia. 4. Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND: Bronchopulmonary dysplasia (BPD) is one of the leading causes of morbidity and mortality in babies born prematurely, yet there is no curative treatment. In recent years, a number of inhibitors against TGFβ signaling have been tested for their potential to prevent neonatal injury associated with hyperoxia, which is a contributing factor of BPD. In this study, we assessed the contribution of activin A-a member of the TGFβ superfamily-to the development of hyperoxia-induced lung injury in neonatal mice. METHODS: We placed newborn C57Bl6 mouse pups in continuous hyperoxia (85% O2) to mimic many aspects of BPD including alveolar simplification and pulmonary inflammation. The pups were administered activin A receptor type IIB-Fc antagonist (ActRIIB-Fc) at 5 mg/kg or follistatin at 0.1 mg/kg on postnatal days 4, 7, 10, and 13. RESULTS: Treatment with ActRIIB-Fc and follistatin protected against hyperoxia-induced growth retardation. ActRIIB-Fc also reduced pulmonary leukocyte infiltration, normalized tissue: airspace ratio and increased septal crest density. These findings were associated with reduced phosphorylation of Smad3 and decreased matrix metalloproteinase (MMP)-9 activity. CONCLUSION: This study suggests that activin A signaling may contribute to the pathology of bronchopulmonary dysplasia.
BACKGROUND:Bronchopulmonary dysplasia (BPD) is one of the leading causes of morbidity and mortality in babies born prematurely, yet there is no curative treatment. In recent years, a number of inhibitors against TGFβ signaling have been tested for their potential to prevent neonatal injury associated with hyperoxia, which is a contributing factor of BPD. In this study, we assessed the contribution of activin A-a member of the TGFβ superfamily-to the development of hyperoxia-induced lung injury in neonatal mice. METHODS: We placed newborn C57Bl6 mouse pups in continuous hyperoxia (85% O2) to mimic many aspects of BPD including alveolar simplification and pulmonary inflammation. The pups were administered activin A receptor type IIB-Fc antagonist (ActRIIB-Fc) at 5 mg/kg or follistatin at 0.1 mg/kg on postnatal days 4, 7, 10, and 13. RESULTS: Treatment with ActRIIB-Fc and follistatin protected against hyperoxia-induced growth retardation. ActRIIB-Fc also reduced pulmonary leukocyte infiltration, normalized tissue: airspace ratio and increased septal crest density. These findings were associated with reduced phosphorylation of Smad3 and decreased matrix metalloproteinase (MMP)-9 activity. CONCLUSION: This study suggests that activin A signaling may contribute to the pathology of bronchopulmonary dysplasia.
Authors: Said A Omar; Amal Abdul-Hafez; Sherif Ibrahim; Natasha Pillai; Mohammed Abdulmageed; Ranga Prasanth Thiruvenkataramani; Tarek Mohamed; Burra V Madhukar; Bruce D Uhal Journal: Cells Date: 2022-04-09 Impact factor: 7.666
Authors: Stefanie Obst; Josephine Herz; Miguel A Alejandre Alcazar; Stefanie Endesfelder; Marius A Möbius; Mario Rüdiger; Ursula Felderhoff-Müser; Ivo Bendix Journal: Oxid Med Cell Longev Date: 2022-02-24 Impact factor: 6.543
Authors: Maria Hurskainen; Ivana Mižíková; David P Cook; Noora Andersson; Chanèle Cyr-Depauw; Flore Lesage; Emmi Helle; Laurent Renesme; Robert P Jankov; Markku Heikinheimo; Barbara C Vanderhyden; Bernard Thébaud Journal: Nat Commun Date: 2021-03-10 Impact factor: 14.919